Vigabatrin

An anticonvulsant that blocks GABA breakdown, FDA-approved for refractory focal seizures and infantile spasms; carries a boxed warning for permanent vision loss.

psilodex.org/m/vigabatrin · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~10.5 h; Approximate, in adults. Source under Interaction below.Effect duration: GABA transaminase inhibition is irreversible, so the effect outlasts the ~10.5 h half-life

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Vigabatrin”, v2026.10.05. psilodex.org/m/vigabatrin

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Refractory complex partial (focal) seizures (add-on, age 2 and older)
Infantile spasms (age 1 month to 2 years)

Sources [1]

Other safety

Boxed warning: permanent bilateral visual field loss, including tunnel vision, which may begin at any time during treatment; available only through a restricted (REMS) program.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

No known interaction with psilocybin, and any effect on it is unknown. Stopping it suddenly after regular use can cause seizures.

Detail Not studied with psilocybin, and no mechanism linking them has been described. Vigabatrin irreversibly blocks GABA breakdown, raising brain GABA (a calming brain chemical); any effect on psilocybin's effects is unknown. Its label reports sleepiness and fatigue. Also, it carries the antiepileptic class warning about suicidality, and stopping it abruptly carries seizure risk. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Effect duration: GABA transaminase inhibition is irreversible, so the effect outlasts the ~10.5 h half-life Label: the duration of drug effect depends on the rate of enzyme re-synthesis rather than on elimination of the drug. Source
Half-life: ~10.5 h (FDA label, checked 2026-10-04) Adults; drug effect depends on enzyme re-synthesis rather than elimination.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Psychiatric reactions: The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Seizure disorder (usual indication)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

SABRIL (vigabatrin) tablet · FDA label (DailyMed) — revised 2025-12 | Psychiatric reactions: 5.5 Suicidal Behavior and Ideation "Antiepileptic drugs (AEDs), including SABRIL, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication." | Sedating or CNS depressant: 5.8 Somnolence and Fatigue "SABRIL causes somnolence and fatigue." | Withdrawal or rebound if stopped abruptly: 5.6 Withdrawal of Antiepileptic Drugs (AEDs) "As with all AEDs, SABRIL should be withdrawn gradually." | 12.1 Mechanism of Action "The duration of drug effect is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug from the systemic circulation." | BOXED WARNING "SABRIL can cause permanent bilateral concentric visual field constriction including tunnel vision that can result in disability ." | 12.3 Pharmacokinetics "10.5 hours for adults"

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →